223690-01-5

Basic information

• Product Name: 4-Cyclopropoxy-benzoic acid Methyl ester
• Synonyms: 4-Cyclopropoxy-benzoic acid Methyl ester
• CAS NO: 223690-01-5
• Molecular Formula: C11H12O3
• Molecular Weight: 192.21118
• EINECS: -0
• Mol File: 223690-01-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Cyclopropoxy-benzoic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cyclopropoxy-benzoic acid Methyl ester(223690-01-5)
• EPA Substance Registry System: 4-Cyclopropoxy-benzoic acid Methyl ester(223690-01-5)

Safety Data

• Hazardous Substances Data: 223690-01-5(Hazardous Substances Data)

Upstream product

• 223690-07-1 4-(1-benzenesulfonyl-cyclopropoxy)-benzoic acid methyl ester 
• 75-11-6 diiodomethane 
• 41074-02-6 4-methoxycarbonylphenyl vinyl ether 
• 1065010-87-8 potassium cyclopropyltrifluoroborate 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 106-41-2 4-bromo-phenol 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 38380-85-7 1-bromo-4-(cyclopropyloxy)benzene 
• 4333-56-6 cyclopropyl bromide 
• 223689-90-5 4-(1-phenylsulfanyl-cyclopropoxy)-benzoic acid methyl ester 

Downstream Products

• 62577-90-6 4-(cyclopropyloxy)benzoic acid 

Relevant articles and documents

S1P1 AGONIST AND APPLICATION THEREOF

The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.

NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION

The present invention relates to the use of piperazinones for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Bolivian, Argentine, Venezuelan, Brazilian, Chapare and